Recent advances in therapeutic approaches for adult T-cell leukemia/lymphoma

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%–5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy has been reportedly promising, particularly in patients with indolent type ATLL; however, the prognosis continues to be dismal for patients with aggressive-type ATLL. Recent efforts to improve treatment outcomes have been focused on the development of prognostic stratification and improved dosage, timing, and combination of therapeutic modalities, such as antiviral therapy, chemotherapy, allogeneic hematopoietic stem cell transplantation, and molecular targeted therapy.

Original languageEnglish
Pages (from-to)6604-6612
Number of pages9
JournalViruses
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 14 2015

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Virology

Cite this